Itamar Medical News
37 articles
growth-positive
Office Tour: Itamar Medical Offices - Caesarea
The article discusses the design of Itamar Medicals new offices in Caesarea, Israel. The design is influenced by medicine and nature, creating a flowing and healing space. The office reflects the companys values and celebrates the brand. Itamar Medical is a medical device company focused on integrating Sleep Apnea management into cardiac patient care. The article has a growth-positive impact on the company.
Customers
growth-positive
ZOLL Medical completes acquisition of Itamar Medical
ZOLL Medical has completed its acquisition of Itamar Medical, a medical device and digital health company. The acquisition will enable ZOLL to enhance its offerings for undiagnosed and untreated cardiac patients. Itamar Medical focuses on developing non-invasive medical devices and solutions to help diagnose respiratory sleep disorders. The companys main product, the WatchPAT Home Sleep Apnea Device, is available in the US, Europe, and Japan. Itamar Medical will now operate as a business division within ZOLL, with the former CEO leading the business. The acquisition closed for approximately $538 million.
Acquisition
growth-positive
Sleep diagnostics company Itamar Medical acquired by ZOLL Medical for $538 million
Israeli medical device and digital health company Itamar Medical has been acquired by ZOLL Medical Corporation for approximately $538 million. Itamar Medical focuses on the development and commercialization of non-invasive medical devices and solutions for the diagnosis of respiratory sleep disorders. ZOLL Medical, an Asahi Kasei company, manufactures medical devices and software solutions. The acquisition will accelerate the advancement of home sleep medicine. The transaction is expected to close by the end of 2021.
Acquisition
growth-positive
Itamar Medical Reports Second Quarter 2021 Financial Results
Itamar Medical Ltd. reported a 41% YoY increase in revenues to $12.6 million for Q2 2021, with U.S. WatchPAT revenues increasing 53% YoY to $10.1 million. The company raised its full-year 2021 revenue guidance to a range of $53 million to $54 million. Itamar Medical added 121 new WatchPAT ONE customers, including 84 new to the company. The companys operating loss for Q2 2021 was $4.6 million, compared to $3.2 million in the same quarter in 2020. As of June 30, 2021, the company had cash, cash equivalents and a short-term bank deposit of $73.0 million.
CustomersInvestment
growth-positive
Itamar's new capabilities include disposable sleep apnea test, subjective sleep data
Israeli sleep apnea company Itamar Medical is expanding the capabilities of its at-home sleep apnea diagnostic testing line, WatchPAT. The new features include WatchPAT with SleePath, which allows users to document subjective data from their test directly in the connected app, and WatchPAT ONE-M, an enhancement to its single-night disposable sleep apnea test. Itamar Medical aims to leverage its growing customer base to transition its WatchPAT app into an active communication tool for patients and physicians. The company plans to provide more information on its product improvements at the Virtual SLEEP 2021 Conference on June 11. Sleep apnea affects a significant number of adults globally, but a large percentage of cases go undiagnosed.
CustomersPartners
growth-positive
Itamar Medical Reports First Quarter 2021 Results
Itamar Medical Ltd. reported a 43% increase in revenues for Q1 2021, reaching $12.0 million. The companys U.S. WatchPAT revenues also saw a 38% increase, reaching $8.4 million. The company gained a total of 725 WatchPAT ONE customers since April 1, 2020, after continuing to onboard approximately 32 new WatchPAT ONE customers per month on average throughout the first quarter. The companys gross profit increased to $8.0 million, compared to $6.3 million in the same quarter in 2020.
CustomersExpand
growth-positive
Itamar Medical raises $70m in Nasdaq offering
Israeli sleep apnea diagnostic devices company Itamar Medical has raised $70 million in a secondary offering on Nasdaq. The company develops and commercializes non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders. Itamars share price rose 7.25% after the offering. Itamar expects increased revenue for the fourth quarter of 2020 and the full year 2020. In January, Itamar acquired Spry Health, a remote patient monitoring solution provider.
Investment
growth-positive
איתמר מדיקל נישאת על גל הבריאות הדיגיטלית - ונסקה לשווי של כמיליארד שקל
איתמר מדיקל, a company that develops and markets non-invasive medical devices for the diagnosis and treatment of sleep disorders, has experienced a 56% growth in the past year due to increased demand for home sleep tests during the COVID-19 pandemic. The pandemic has accelerated the digital health sector, connecting patients with healthcare providers online. Prior to the pandemic, only one-third of sleep tests in the US were conducted at home, while the majority were done in sleep labs. However, the reality has changed with the pandemic. The article highlights the growing importance of digital health and the impact it has had on the companys growth.
Customers
growth-positive
Itamar Medical Acquires Technology and Assets of Spry Health
Itamar Medical has announced its acquisition of technology and assets from Spry Health, a San Francisco-based company that develops a wrist-based medical grade remote patient monitoring (RPM) solution. The acquisition will allow Itamar to develop a continuous sleep apnea monitoring device, expanding its presence in sleep apnea diagnostics and chronic disease management. The acquisition also provides an opportunity for market expansion in the home health monitoring solutions market and potential new revenue opportunities. Itamar plans to commence development of the new wrist-worn device immediately, with an anticipated market launch in 2022. The total global RPM market is estimated to reach $2 billion in 2027. The acquisition will enable Itamar to offer an end-to-end digital care pathway for sleep apnea management and cardiovascular disease.
PartnersExpand
growth-positive
Itamar Medical Reports Record Third Quarter 2020 Revenues
Itamar Medical Ltd. reported a 36% increase in third quarter revenues to $11.0 million, with U.S. WatchPAT revenues increasing by 55% to $8.9 million. The companys growth was driven by the shift to home-based care and strong demand in the U.S. across almost all geographies and verticals. Itamar Medical also reinstated its full year 2020 revenue guidance to a range of $39.5 million to $40.5 million. The companys financial results were unaudited.
CustomersExpand
growth-positive
Itamar Medical wins National Sleep Foundation award
Itamar Medical has been named the winner of the 2020 SleepTech Award for its innovative achievement in sleep technology. The company, based in Caesarea, Israel, and Atlanta, Georgia, develops non-invasive devices and solutions for the diagnosis of respiratory sleep disorders. Its product, WatchPAT ONE, is a disposable home sleep apnea test that connects to a smartphone app and transmits sleep data for review. Itamar Medicals focus on customer insights and needs, particularly during the COVID-19 pandemic, has been recognized by the National Sleep Foundation. The CEO of Itamar Medical highlights the underdiagnosis and undertreatment of sleep apnea, and the companys commitment to providing simple and reliable solutions for diagnosis and management without the need for patients to leave home or be exposed to infection.
Customers
growth-positive
Itamar Medical Announces Appointment of Shane Brown as President - U.S.
Itamar Medical has appointed Shane Brown as President - U.S. to oversee commercial strategy and execution in the U.S. market. The company aims to accelerate its investment in the penetration of the U.S. market, particularly in the sleep apnea sector. Brown brings over 20 years of commercial experience in the medical device industry, with a focus on cardiology. Itamar Medicals recent growth has been driven by the adoption of its WatchPAT ONE product by sleep centers. The company aims to expand its reach to the estimated 54-60 million adults in the U.S. suffering from sleep apnea.
Management ChangesExpand
growth-positive
Itamar Medical's WatchPAT™300 Home Sleep Apnea Testing Device Receives Approval in Japan
Itamar Medicals WatchPAT™300 Home Sleep Apnea Testing device has received PMDA approval for use in the Japanese market. The device will be made available in Japan through Itamar Medicals exclusive distributor, Philips Japan Co. Itamar Medical is a medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders. The company aims to provide an easy access solution for the undiagnosed and untreated sleep apnea patient population. Sleep apnea affects approximately one billion people worldwide. Itamar Medicals WatchPAT™ is an FDA-approved device used for diagnosing sleep apnea at home.
CustomersPartners
growth-positive
As sleep patients stay home, Itamar Medical's time arrives
Itamar Medical, a medical device company, has experienced significant growth in 2020, with its share price doubling and its market cap reaching NIS 1.2 billion. The company is expected to report a substantial increase in revenue for the second quarter, driven by its main offering, a perishable product for diagnosing sleep apnea. The COVID-19 pandemic has accelerated the shift towards home diagnostic activity, benefiting Itamar Medical as sleep clinics have been closed or discouraged for diagnosis. The company has grown its market share in the home test market for sleep apnea, surpassing its competitors. Itamar Medical plans to continue focusing on the sleep apnea market and sees potential for growth in collaborations and acquisitions. The company is financially stable with $50 million in cash. The article was published on August 5, 2020.
CustomersExpand
growth-positive
Itamar Medical Receives CE Mark Approval for its WatchPAT™ ONE, the First Fully Disposable Home Sleep Apnea Test
Itamar Medical Ltd. has received CE mark approval for its WatchPAT ONE, a home-based solution for diagnosing respiratory sleep disorders. This approval allows the company to expand commercialization of the product in Europe and other CE Mark geographies. The WatchPAT ONE is a fully disposable Home Sleep Apnea Test (HSAT) that eliminates the need for return shipping, downloading, cleaning, and preparation, reducing patient and staff exposure. Itamar Medical is focused on the development and commercialization of non-invasive medical devices and solutions for respiratory sleep disorders. The companys key product, WatchPAT, is already available in major markets including the US, Japan, and Europe.
CustomersExpand
growth-positive
Itamar™ Medical Funds Clinical Study to Evaluate Potential Impact of CPAP Therapy to Patients with COVID-19
Itamar Medical has initiated a funded trial to evaluate the use of CPAP in managing patients with confirmed or suspected COVID-19. The study aims to determine if early, low, fixed CPAP at home reduces the risk of hospital/ER re-admission or death in COVID-19 patients. It will also assess if obstructive sleep apnea (OSA) and obesity are risk factors for hospitalizations, mechanical ventilation, and/or death in COVID-19 patients. The study will involve 200 patients within the Mount Sinai Health System in New York City. Itamar Medicals WatchPAT technology will be used to determine sleep apnea status. The study is expected to provide insights into the role of CPAP in managing COVID-19 patients at home and reducing the burden on the healthcare system.
CustomersPartners
growth-positive
Itamar™ Medical and BetterNight to Join Forces Offering Referred Patients Home Based Virtual-Care Sleep Solution for the Diagnosis and Treatment of Sleep Apnea
Itamar Medical has entered into an agreement with Sleep Data Diagnostics and BetterNight to simplify the process of sleep apnea testing and treatment. The agreement aims to increase patient access to testing and provide a full care pathway for physicians and their patients. Itamar Medical will provide diagnostic studies and facilitate consultations with physicians, while BetterNight will provide home-based CPAP therapy care. The integration of Itamar Medicals digital platform with BetterNights remote therapy set up is expected to improve the rate of conversion from diagnosis to treatment. The standard care pathway for sleep apnea includes multiple in-person visits, resulting in many patients remaining undiagnosed. Itamar Medical and BetterNight aim to address this issue and improve sleep care management.
PartnersCustomers
growth-positive
Itamar™ Medical Implements Broad Range of Actions in Response to COVID-19 Pandemic
Itamar Medical, a medical technology company, released a letter from its President and CEO addressing the impact of COVID-19 on the company. The companys non-production employees are working from home to ensure business continuity. Itamar Medical has a strong cash position and does not expect a material impact on its first quarter financial results. The company is focused on providing non-invasive medical devices for the diagnosis of respiratory sleep disorders, particularly sleep apnea. The recent government response to COVID-19 has affected the regular business activities of the companys customers, but the company remains committed to supporting at-home diagnosis and therapy for sleep apnea patients.
CustomersPartners
growth-positive
Itamar™ Medical and Clalit Research Institute Establish Research Collaboration to Explore WatchPAT Signals' Ability to Predict Health Outcomes Using Existing Big Data and Artificial Intelligence
Itamar Medical has entered into a research collaboration agreement with Clalit Research Institute to conduct a study on using data from the WatchPAT signal to predict cardiovascular health outcomes. The study will use artificial intelligence tools to compare predictive models for different outcomes such as cardiovascular disease and congestive heart failure. Approximately 50,000 patients within the Clalit Health Services network have undergone WatchPAT testing over the past 10 years. The study is anticipated to take two years.
Partners
growth-positive
Itamar Medical Closes Nasdaq Public Offering at $40.25 Million
Itamar Medical Ltd. has closed its public offering of American Depositary Shares (ADS) on Nasdaq at $40.25 million. The company initially looked to raise $30 million but increased its offering due to demand. Itamar Medical develops and manufactures non-invasive diagnostic devices for sleep disorders and cardiovascular diseases.
Investment
growth-positive
Itamar Medical Selected to Participate in the Prestigious Weizmann Institute Project 10K
Itamar Medicals WatchPAT home sleep apnea diagnostic system has been selected for inclusion in the Weizmann Institutes Project 10K. The project aims to collect lifestyle and clinical data from 10,000 individuals over ten years and use artificial intelligence to analyze the data for personalized disease risk predictions. Itamar will provide 150,000 WatchPAT tests for the diagnosis and monitoring of sleep apnea as part of the project. The inclusion of WatchPAT highlights the importance of understanding sleep disorders in preventing and managing the risk of heart disease and stroke. Itamar Medical is a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market.
Partners
growth-positive
Itamar Medical Receives FDA Approval for Sleep Apnea Monitor
Itamar Medical Ltd. has received FDA approval for its home monitor for sleep apnea, called WatchPAT One. The newly approved product is a one-use version of the companys existing product, WatchPAT 300, and retails for $100, significantly cheaper than the previous products price of $5,000. Itamar Medical develops and manufactures non-invasive diagnostic devices for sleep disorders and cardiovascular diseases. The approval of WatchPAT One is expected to have a positive impact on the companys growth. The article does not mention any specific partners, customers, or investment/acquisition details. The event described in the article occurred on June 6, 2019.
Customers
growth-positive
Itamar Expands Collaboration with Cardiac Monitoring Company to Expand Sleep Offerings to Cardiology Patients
Itamar Medical has expanded its collaboration with BioTel Heart to make its Total Sleep Solution available to select BioTel Heart cardiology customers in the US. The collaboration aims to meet the growing demand for home sleep apnea testing among cardiologists. Itamar Medicals Total Sleep Solution offers a comprehensive program that includes products and services for sleep apnea management. BioTel Heart, a division of BioTelemetry Inc, processes billions of heartbeats per day and monitors over a million patients annually. The collaboration allows cardiologists to prescribe home sleep apnea tests without pre-authorization and billing concerns, simplifying the integration of Itamar Medicals offering into routine cardiac care pathways.
CustomersPartners
growth-positive
Lofta Partners with Itamar Medical for Home Sleep Testing
Lofta, a mail-order sleep apnea diagnostic and treatment company, has entered into a commercial agreement with Itamar Medical Ltd for home sleep testing devices. Lofta will integrate Itamars diagnostic tool into its process, providing a simple and accessible solution for sleep apnea diagnosis and treatment. The partnership aims to make the sleep apnea diagnosis process more convenient and user-friendly, allowing clients to receive comprehensive treatment support from the comfort of their homes. Loftas director of client services emphasizes the importance of treating sleep apnea and the companys commitment to staying with clients throughout their journey. The article does not mention any specific customers, investment or acquisition amounts, layoffs, or the date of the event.
Partners
growth-positive
Itamar Medical launches next-generation WatchPAT system for home sleep apnea testing
Itamar Medical has announced the launch of WatchPAT 300, a next-generation system for home sleep apnea testing. WatchPAT 300 utilizes peripheral arterial tone and other signals to accurately diagnose both obstructive and central sleep apnea. The system aims to address the challenge of diagnosing the millions of patients with undiagnosed sleep apnea in a simple, accurate, and scalable manner. Itamar Medical believes that WatchPAT 300 can play a critical role in solving this challenge. The system has an intuitive and comfortable design and includes a Central+ module for specific identification of Central Sleep Apnea events. WatchPAT 300 was granted 510(k) clearance by the FDA and will gradually replace the current WatchPAT 200 platform.
Customers
growth-positive
Itamar Medical Advances Simple, Accurate and Reliable Home Sleep Apnea Testing with Launch of WatchPAT™ 300
Itamar Medical has announced the launch of WatchPAT 300, the next generation WatchPAT system for home sleep apnea testing. The new system includes several advances that enhance patient comfort and simplify physician workflow. It utilizes peripheral arterial tone and other signals to accurately diagnose both obstructive and central sleep apnea. WatchPAT 300 has an intuitive and more comfortable design, with three points of contact and without cumbersome nasal canula or chest belts. It also provides clinically validated sleep architecture and reduces the risk of misdiagnosis. The system was granted 510(k) clearance by the FDA and will be presented at SLEEP 2019. Itamar Medical is a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea.
Customers
growth-positive
Itamar Medical Starts Trading ADS on Nasdaq
Tel Aviv-listed medical diagnosis company Itamar Medical Ltd. has started trading its American Depositary Shares (ADS) on Nasdaq. The company received approval from the U.S. Securities and Exchange Commission to list its ADSs. Itamar Medical develops and manufactures FDA-approved non-invasive diagnostic devices for sleep disorders and cardiovascular diseases. In January, the company announced it has signed agreements to raise $11.5 million in private placement.
Public Trading
growth-positive
Itamar Medical Announces that Publication on the Role of Obstructive Sleep Apnea in Atrial Fibrillation Selected for Inclusion in Circulation's 2018 Year in Review
Itamar Medicals article on the association between obstructive sleep apnea and atrial fibrillation has been selected for inclusion in the 2018 Year in Review of Circulation: Arrhythmia and Electrophysiology. The article highlights the need for conducting sleep studies in all atrial fibrillation patients and the importance of diagnosing and managing obstructive sleep apnea in these patients. Itamar Medicals WatchPAT device, used in the study, offers a cost-effective solution for conducting sleep studies in the patients home. The articles inclusion in the Year in Review reflects the significance of the findings for managing atrial fibrillation patients and reducing the risk of recurrence post ablations.
Customers
growth-positive
Itamar Medical Partners with CardioVisual to Educate Patients and Healthcare Providers on the Importance of Sleep Apnea Testing and Streamline Cardiology Practice Workflow
Itamar Medical has announced a digital education partnership with CardioVisual to educate cardiovascular patients and physicians on the importance of diagnosing and treating sleep apnea. The partnership aims to improve patient outcomes and streamline cardiology practice workflow. The educational program will be delivered through CardioVisuals multimedia interactive heart health app, which will include videos describing the importance of diagnosing and treating sleep apnea and the clinical benefits of Itamar Medicals WatchPAT home sleep apnea testing device. The partnership will help raise awareness among patients and clinicians about the role that WatchPAT may play in heart health.
Partners
growth-positive
Itamar Medical raises $11.5m
Sleeping disorders diagnosis company Itamar Medical Ltd. has raised $11.5 million in a private bridging placement as it prepares for a public offering in the US. The round was led by US investors and included Israeli investor More Investment House. The companys share price for the round was NIS 1.17, a 16% discount on the market price. Itamar Medical has developed a system for home diagnosis of breathing disorders during sleep and has seen a 14.7% increase in revenue in the third quarter of 2018. The companys CEO is Gilad Glick.
Investment
growth-positive
Itamar Medical Announces Favorable CMS Reimbursement Decision to its WatchPAT™ Sleep Apnea Testing Device
Itamar Medical announces the release of the 2019 Fee Schedule from the U.S. Centers for Medicare & Medicaid Services (CMS), which is expected to support the use of its WatchPAT technology. WatchPAT is a non-invasive diagnostic medical device for sleep apnea that uses Peripheral Arterial Tone (PAT) technology. The company estimates that WatchPAT accounted for approximately 15% of home sleep tests in the United States in 2017. The new CMS Fee Schedule is seen as validating the clinical value of Itamar Medicals sleep tests and may significantly increase their utilization in the U.S. market. Itamar Medical focuses on integrating sleep apnea management into the cardiac care pathway with its Total Sleep Solution.
Customers
growth-positive
Itamar Medical to list on Nasdaq
Itamar Medical, an Israeli company that develops home devices for diagnosing sleep apnea, has announced its intention to be listed on Nasdaq. The company has already filed its request for listing with the US Securities and Exchange Commission. Itamar Medicals share price rose 3.6% following the announcement, and its market cap increased to NIS 339 million. The company has shown stable growth in revenue, with a 20% increase in the second quarter compared to the previous year. Itamar Medical hopes to obtain approval for its next-generation sleep apnea diagnosis product by mid-2019. The company sees potential in the US market and aims to exceed $20 million in revenue for 2018. Nasdaq has become more favorable to medical device companies, and Itamar Medical sees itself as comparable to successful companies in the field.
Public Trading
growth-positive
Itamar Medical Highlights New WatchPAT™ Scoring Guidelines Based on the COMPASS(1) Study Results from Johns Hopkins Sleep Investigators at SLEEP 2018
Itamar Medical plans to unveil the WatchPAT Scoring Guidelines, a streamlined approach for reviewing and editing WatchPAT data that integrates automated scoring with visual oversight. The guidelines were developed by researchers at Johns Hopkins Sleep Disorder Center and will be presented at a symposium hosted by Itamar Medical. WatchPAT is an FDA-approved portable diagnostic device for sleep apnea testing. The guidelines aim to facilitate the use of WatchPAT and potentially reduce costs to the healthcare system. Itamar Medical is a company that develops, manufactures, and markets non-invasive diagnostic medical devices for cardiology and sleep-related breathing disorders.
Customers
growth-positive
Itamar Medical - a sleeping giant?
Itamar Medical, a medical device company, is looking to expand its market to younger ages, between 12 and 17. The companys device, the WatchPAT, is a home sleep testing device for the diagnosis of Sleep Breathing Disorders (SBD). The device has been found to help with weight gain issues, as many of the regulatory processes of the body, including proper metabolism, occur during the REM phase of sleep. The company recently signed a marketing agreement with Medtronic, one of the worlds largest cardiology companies. Under this agreement, Medtronic will promote Itamars product among cardiologists.
CustomersPartnersInvestment
growth-positive
Viola PE to invest up to $28m in Itamar Medical
Viola Private Equity has announced a private investment in public equity (PIPE) deal, of up to $28.4 million in Itamar Medical Ltd. The deal will make Viola Private Equity the largest shareholder in the cardiovascular and sleep apnea diagnostics company. Itamar Medical will issue shares to Viola Private Equity at the price of NIS 1.449 per share for consideration of $24.1 million. Itamar Medical will also issue non-tradable warrants for the acquisition of up to 50% of issued shares. Itamar Medical plans to initiate a rights offering to existing shareholders to invest an additional $5.9 million. The major shareholders of Itamar Medical also intend to convert their existing $1.6 million shareholders loan to equity. Viola Private Equity and the major shareholders agreed that all of their shares in the company will be locked-down for a period of 18 months. Viola Private Equity will have two representatives on Itamar Medicals Board of Directors.
Investment
growth-positive
Itamar Medical signs distribution deal in Japan
Itamar Medical has signed a strategic marketing and distribution agreement with Nihon Kohden in Japan. Nihon Kohden will market Itamars EndoPAT diagnostic tool to doctors and hospitals in Japan. Itamar Medical has seen steady growth in its revenue from cardiology products and considers Japan and the US as its main target markets. The agreement with Nihon Kohden has the potential to boost its sales growth. The market for EndoPAT in the fields of heart disease, preventative medicine, and internal medicine in Japan, the US, and Europe is worth $2.6 billion annually. Itamar Medical believes that Nihon Kohden is an excellent partner for introducing the EndoPAT diagnostic tool in the Japanese market.
Partners
growth-positive
Diagnose heart disease with a fingertip test [video]
Itamar Medical, an Israeli company, has developed a fingertip test that can diagnose sleep apnea and heart disease at an earlier stage. The devices, called WatchPAT and EndoPAT, use Peripheral Arterial Tone (PAT) to monitor pulses in the fingertips or extremities. WatchPAT is worn on the wrist and can diagnose sleep apnea in a wireless situation from home. The information is then analyzed by a doctor using software. EndoPAT measures the flexibility of arteries in the finger to predict the development of heart disease. Itamar Medicals technology is already being used by Kaiser Permanente in the US. The companys growth is expected to be positive due to the innovative nature of its products.
Customers
